Kathleen Moore, MD | Authors


Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian Cancer

November 15, 2019

Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.